Ephraim A. Ansa-Addo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ephraim A. Ansa-Addo has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Dongjun Chung
Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA
2 shared publications - Huai-Cheng Huang
National Taiwan University College of Medicine, Graduate Institute of Clinical Medicine, Taipei City, Taiwan, ROC
2 shared publications Parviz Azimnasab-Sorkhabi
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA
2 shared publications- Zihai Li
Pelotonia Institute for Immuno-Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, USA
2 shared publications Afryea Henderson
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, USA
1 shared publication- Allan Tsung
Department of Surgery University of Virginia Charlottesville Virginia USA
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment
- 7 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe chromatin-organizer Satb1 modulates regulatory T cell activity within the tumor microenvironment
- Open Access
- 17 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1658576
Hybrid regulatory T cells: camouflaged architects of tumor immunity
Distinct from conventional Foxp3+ regulatory T cells (Tregs), T-bet+ Tregs represent a stable subset of immunosuppressive T cells characterized by co-expression of the transcription factors (TFs) Foxp3 and T-bet. Given that Tregs were also reported to co-express Foxp3 together with effector T cell TFs such as GATA3, or RORγt, we propose the term hybrid Tregs (hTregs) to distinguish between these Tregs that co-express Foxp3 together with effector T cell TFs from conventional Foxp3+ Tregs. Therefore, this review will focus on hTreg cells, a specific subset of CD4+ T cells, and discuss the different types of hTregs with particular emphasis on T-bet+ hTregs. T-bet+ hTregs exhibit unique features including IFN-γ production, high expression of immune checkpoints (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5). Through secretion of IL-10, TGF-β and IFN-γ, T-bet+ hTregs modulate both innate and adaptive immune responses within the tumor microenvironment (TME). Their high expression of CD73 contributes to adenosine-mediated immunosuppression, while CXCR3 and CCR5 facilitate their recruitment to inflammatory sites. T-bet+ hTregs were reported to accumulate in multiple human cancers, including lung, ovarian, and colorectal carcinomas. Despite these advancements, the function of hTregs in diseases such as cancer remains poorly understood, and requires further investigations. For instance, some studies suggest T-bet+ hTregs to be anti-inflammatory due to their production of IL-10, TGF-β, and superior suppressive capacity compared to conventional Tregs. Yet, other studies have reported that T-bet+ hTregs exhibit enhanced proinflammatory functions in colitis and other pathologies. We will then highlight current known mechanisms that promote the differentiation and functions of T-bet+ hTregs in cancer. Lastly, we will discuss the advancements and opportunities for therapeutic targeting of T-bet+ hTregs in cancer immunotherapy.
- 17 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1658576
Open AccessHybrid regulatory T cells: camouflaged architects of tumor immunity
Distinct from conventional Foxp3+ regulatory T cells (Tregs), T-bet+ Tregs represent a stable subset of immunosuppressive T cells characterized by co-expression of the transcription factors (TFs) Foxp3 and T-bet. Given that Tregs were also reported to co-express Foxp3 together with effector T cell TFs such as GATA3, or RORγt, we propose the term hybrid Tregs (hTregs) to distinguish between these Tregs that co-express Foxp3 together with effector T cell TFs from conventional Foxp3+ Tregs. Therefore, this review will focus on hTreg cells, a specific subset of CD4+ T cells, and discuss the different types of hTregs with particular emphasis on T-bet+ hTregs. T-bet+ hTregs exhibit unique features including IFN-γ production, high expression of immune checkpoints (PD-1, CTLA-4, GITR, OX40, TIGIT), and chemokine receptors (CXCR3, CCR5). Through secretion of IL-10, TGF-β and IFN-γ, T-bet+ hTregs modulate both innate and adaptive immune responses within the tumor microenvironment (TME). Their high expression of CD73 contributes to adenosine-mediated immunosuppression, while CXCR3 and CCR5 facilitate their recruitment to inflammatory sites. T-bet+ hTregs were reported to accumulate in multiple human cancers, including lung, ovarian, and colorectal carcinomas. Despite these advancements, the function of hTregs in diseases such as cancer remains poorly understood, and requires further investigations. For instance, some studies suggest T-bet+ hTregs to be anti-inflammatory due to their production of IL-10, TGF-β, and superior suppressive capacity compared to conventional Tregs. Yet, other studies have reported that T-bet+ hTregs exhibit enhanced proinflammatory functions in colitis and other pathologies. We will then highlight current known mechanisms that promote the differentiation and functions of T-bet+ hTregs in cancer. Lastly, we will discuss the advancements and opportunities for therapeutic targeting of T-bet+ hTregs in cancer immunotherapy.
- 29 August 2024
- Published by Springer Nature
- p. 143-189
Conventional T Cell Subsets and Their Roles Within the Tumor Microenvironment
- 29 August 2024
- Published by Springer Nature
- p. 143-189
Conventional T Cell Subsets and Their Roles Within the Tumor Microenvironment
- Top Cited Papers
- 1 December 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 75 (6) , 1271-1283
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis
- 1 December 2021
- Published by Elsevier in Journal of Hepatology
- Vol. 75 (6) , 1271-1283
Top Cited PapersRegulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis
- Open Access
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaaz3865
RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity
Distinct lineages of T cells can act in response to various environmental cues to either drive or restrict immune-mediated pathology. Here, we identify the RNA binding protein, poly(C)-binding protein 1 (PCBP1) as an intracellular immune checkpoint that is up-regulated in activated T cells to prevent conversion of effector T (Teff) cells into regulatory T (Treg) cells, by restricting the expression of Teff cell–intrinsic Treg commitment programs. This was critical for stabilizing Teff cell functions and subverting immune-suppressive signals. T cell–specific deletion of Pcbp1 favored Treg cell differentiation, enlisted multiple inhibitory immune checkpoint molecules including PD-1, TIGIT, and VISTA on tumor-infiltrating lymphocytes, and blunted antitumor immunity. Our results demonstrate a critical role for PCBP1 as an intracellular immune checkpoint for maintaining Teff cell functions in cancer immunity.
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaaz3865
Open AccessRNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity
Distinct lineages of T cells can act in response to various environmental cues to either drive or restrict immune-mediated pathology. Here, we identify the RNA binding protein, poly(C)-binding protein 1 (PCBP1) as an intracellular immune checkpoint that is up-regulated in activated T cells to prevent conversion of effector T (Teff) cells into regulatory T (Treg) cells, by restricting the expression of Teff cell–intrinsic Treg commitment programs. This was critical for stabilizing Teff cell functions and subverting immune-suppressive signals. T cell–specific deletion of Pcbp1 favored Treg cell differentiation, enlisted multiple inhibitory immune checkpoint molecules including PD-1, TIGIT, and VISTA on tumor-infiltrating lymphocytes, and blunted antitumor immunity. Our results demonstrate a critical role for PCBP1 as an intracellular immune checkpoint for maintaining Teff cell functions in cancer immunity.